The highly diverse and innovative pipeline for Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) treatment has the potential to produce therapies that will help repair the mutated gene, halt muscle degeneration, and improve patients’ life expectancy, according to new research. 13 May 2015
US biopharma company Arena Pharmaceuticals has entered into a development, marketing and supply agreement with Roivant Sciences for nelotanserin, Arena's internally discovered inverse agonist of the 5-HT2A receptor. 12 May 2015
The US Food and Drug Administration issued a Complete Response letter regarding the supplemental New Drug Application for once-monthly long-acting antipsychotic Invega Sustenna (paliperidone palmitate) filed by Janssen Pharmaceuticals. 12 May 2015
US drugmaker Endo International has acquired a broad portfolio of branded and generic injectable and established products from a subsidiary of South Africa’s leading pharma company Aspen Holdings. 11 May 2015
UK cannabinoid specialist GW Pharmaceuticals has announced financial results and the initiation of a Phase III study of Epidiolex (cannabidiol). 11 May 2015
Fycompa (perampanel), the first-in-class drug for partial-onset seizures, manufactured by Japanese drug major Eisai, is now available in Italy. 11 May 2015
Japanese drug majors Sumitomo Dainippon Pharma and Takeda Pharmaceutical sare terminating their license agreement for the joint development and exclusive commercialization in Europe of pharmaceutical products containing lurasidone hydrochloride (brand name Latuda), an atypical antipsychotic agent. 7 May 2015
Danish CNS specialist Lundbeck this morning reported first-quarter 2015 financial results, with core revenue of 3.56 billion Danish kroner ($535.8 million), a dip of 1% (-10% in local currencies) compared with the like period of 2014. 6 May 2015
UK-based Indivior today released encouraging top-line results from its Phase III clinical trial of RBP-7000, an investigational drug in development for the treatment of schizophrenia. 5 May 2015
New Jersey, USA-based Braeburn Pharmaceuticals has expanded its current therapeutic focus beyond addiction and pain to include schizophrenia and other serious psychiatric disorders. 4 May 2015
Japanese drug major Eisai has entered into a settlement agreement with Indian drugmaker Glenmark Pharmaceuticals and its US subsidiaries to resolve their patent litigation relating to Eisai's Banzel (rufinamide) in the USA. 1 May 2015
The US Food and Drug Administration yesterday approved the first generic versions of Bristol-Myers Squibb and Japanese drugmaker Otsuka Pharmaceutical’s Abilify (aripiprazole). 29 April 2015
Privately held French biotechnology firm MedDay has announced positive results from the pivotal Phase III clinical trial, MS-SPI, with its multiple sclerosis drug candidate MD1003, at the annual meeting of the American Academy of Neurology. 27 April 2015
Of the five marketing approval requests reviewed at the April 2015 meeting of the European Medicines agency’s Committee for Medicinal Products for Human Use (CHMP), four received a positive opinion, and one did not. 25 April 2015
A total of seven generic drugs were recommended for approval at the April 2015 meeting of the European Medicines agency’s Committee for Medicinal Products for Human Use (CHMP). 25 April 2015
Israel-based Teva Pharmaceutical Industries has agreed a $512 million settlement in a class-action law suit in which a company it owns was accused of delaying the launch of Provigil (modafinil). 21 April 2015
Today, the US Food and Drug Administration approved Miplyffa (arimoclomol), an oral medication for the treatment of Neimann-Pick disease, type C (NPC). 20 September 2024
US neuroscience company BioXcel Therapeutics has announced a new clinical prioritization and an update on its late-stage development programs for the treatment of agitation with BXCL501. 20 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US clinical stage CNS drug developer Athira Pharma is taking decisive action following the company’s announcement of disappointing data from the Phase II/III LIFT-AD clinical trial of fosgonimeton to treat Alzheimer’s disease (AD). 18 September 2024
The US Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), from Swiss pharma giant Roche. 16 September 2024
US pharma major Eli Lilly has announced a $1 billion expansion of its manufacturing site in Limerick, Ireland, to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease. 13 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
The global migraine market in mature economies is projected to grow from $9.2 billion in 2023 to $16.4 billion by 2033, according to a report from GlobalData. 10 September 2024
Cartesian Therapeutics today announced that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). 9 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
The cost of prescribed dependency-forming medicines has decreased by £410 million ($539.6 million) since 2015/16, according to newly released data from the UK’s National Health Service (NHS). 6 September 2024
Shares in US biopharma Axsome Therapeutics, a biopharmaceutical company developing and delivering novel therapies for the management of CNS disorders, closed 7% higher on Wednesday. 5 September 2024
Mid-Atlantic BioTherapeutics (MABT) has announced a collaboration with Accelero Biostructures to identify novel inhibitors of USP30, a protein linked to neurological disorders and other conditions. 5 September 2024
Praxis Precision Medicines shared positive top-line results for its Phase II, proof of concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy (DEE) patients. 4 September 2024